Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that
develops and commercializes biologic products to improve
compatibility between medical devices and the patients who need
them, today provided a business update and reported financial
results for the first quarter ended March 31, 2023.
Business Highlights:
- Net sales rose
14% compared to the prior-year period, to a record $13.1 million
for first quarter 2023.
- Gross margin
increased 11 percentage points year-over-year to 49%.
- Signed a
partnership with LeMaitre Vascular to distribute Aziyo’s
cardiovascular repair portfolio within the U.S., increasing sales
representative coverage 5-fold.
- Launched a U.S.
distribution partnership with Sientra to drive availability and
utilization of SimpliDerm.
- Held a
productive meeting with the U.S. Food and Drug Administration (FDA)
confirming the path to resubmit CanGaroo® RM 510(k) for pre-market
clearance.
“Aziyo’s record first quarter performance is a
testament to our products, people and plan,” said Dr. Randy Mills,
President and Chief Executive Officer of Aziyo Biologics. “The
company charged forward with strong results on all fronts,
highlighted by the highest quarterly net sales and gross profit in
company history. We also made great progress in the strategic
evolution of Aziyo, closing two key partnerships with LeMaitre
Vascular and Sientra, thereby significantly boosting the sales
coverage of our cardiovascular and SimpliDerm product lines.
Lastly, we met with the FDA and are executing a plan to deliver the
Agency the information it requested in connection with the
clearance of CanGaroo RM. Thank you to the entire Aziyo team for
your grit and determination in delivering a great performance.”
First Quarter 2023 Financial Results
Net sales for the first quarter of 2023 were
$13.1 million, an increase of 14% compared to the first quarter of
2022. Growth was achieved in all four of the Company’s major
product categories, led by SimpliDerm and CanGaroo, for which net
sales grew 40% and 14%, respectively, versus the first quarter of
2022.
Gross profit for the first quarter of 2023 was
$6.3 million and gross margin was 49%, as compared to $4.3 million
and 37%, respectively, in the corresponding prior-year period.
Gross margin, excluding intangible asset amortization (a measure
not presented in accordance with U.S. generally accepted accounting
principles (“GAAP”)) was 55% for the first quarter of 2023, as
compared to 45% in the first quarter of 2022. The increase in gross
margin was primarily due to efficiency and yield improvements in
the Company’s Orthobiologics and Women’s Health business units.
Total operating expenses were $12.7 million for
the first quarter of 2023, as compared to $11.2 million in the
corresponding prior-year period.
Net loss was $8.0 million in the first quarter
of 2023, as compared to $8.1 million in the corresponding prior
year period. Net loss per share in the first quarter of 2023 was
$0.49 per share, as compared to a loss of $0.60 per share in the
first quarter of 2022.
Aziyo’s cash balance as of March 31, 2023, was
$11.8 million.
Conference Call
Aziyo will host a conference call today at 4:30
p.m. Eastern Time / 1:30 p.m. Pacific Time to discuss its first
quarter 2023 financial results and performance.
Individuals interested in listening to the
conference call are required to register online. Participants are
recommended to register at least 15 minutes before the start of the
call. A live and archived webcast of the event and the accompanying
presentation materials will be available on the “Investors” section
of the Aziyo website at https://investors.aziyo.com/.
About Aziyo Biologics
Aziyo develops and commercializes biologic
products to improve compatibility between medical devices and the
patients who need them. With a growing population in need of
implantable technologies, Aziyo’s mission is to humanize medical
devices to improve patient outcomes. For more information, visit
www.Aziyo.com.
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Forward-looking statements can be identified
by words such as “projects,” “may,” “will,” “could,” “would,”
“should,” “believes,” “expects,” “anticipates,” “estimates,”
“intends,” “plans,” “potential,” “promise” or similar references to
future periods. All statements contained in this press release that
do not relate to matters of historical fact should be considered
forward-looking statements, including statements and information
concerning the effectiveness of our products, the ability to expand
availability of our products as a result of our distribution
arrangements with LeMaitre Vascular and Sientra, the potential
success of our distribution arrangements with LeMaitre Vascular and
Sientra, and our expectations relating to the FDA regulatory
process for the CanGaroo RM Antibacterial Envelope. Forward-looking
statements are based on management’s current assumptions and
expectations of future events and trends, which affect or may
affect our business, strategy, operations or financial performance,
and actual results may differ materially from those expressed or
implied in such statements due to numerous risks and uncertainties.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted or quantified, and
other important factors that may cause actual results, performance
or achievements to differ materially from those contemplated or
implied in this press release, including, but not limited to, risks
regarding the ability to successfully execute or realize the
anticipated benefits under our distribution arrangements with
LeMaitre Vascular and Sientra; our inability to generate sufficient
revenue to achieve or sustain profitability; adverse changes in
economic conditions and instability and disruption of credit
markets; our ability to continue as a going concern; our products
and our ability to enhance, expand, develop and commercialize our
product offerings; the impact on our business of the recall of a
single lot of our FiberCel product and the discontinuation of its
sales by our distribution partner; our dependence on our commercial
partners; physician awareness of the distinctive characteristics,
and acceptance by the medical community, of our products; the
ability to obtain regulatory approval or other marketing
authorizations; and our intellectual property rights, and other
important factors which can be found in the “Risk Factors” section
of Aziyo’s public filings with the Securities and Exchange
Commission (“SEC”), including Aziyo’s Annual Report on Form 10-K
for the year ended December 31, 2022, as such factors may be
updated from time to time in Aziyo’s other filings with the SEC,
including, Aziyo’s Quarterly Reports on Form 10-Q, accessible on
the SEC’s website at www.sec.gov and the Investor Relations page of
Aziyo’s website at https://investors.aziyo.com. Because
forward-looking statements are inherently subject to risks and
uncertainties, you should not rely on these forward-looking
statements as predictions of future events. Any forward-looking
statement made by Aziyo in this press release is based only on
information currently available and speaks only as of the date on
which it is made. Except as required by applicable law, Aziyo
expressly disclaims any obligations to publicly update any
forward-looking statements, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise.
Investors:Matt SteinbergFINN
Partnersmatt.steinberg@finnpartners.com
Media:Courtney GuyerAziyo Biologics,
Inc.PR@aziyo.com
|
AZIYO BIOLOGICS, INC. |
CONSOLIDATED BALANCE SHEET DATA |
(Unaudited, in thousands) |
|
|
|
|
Assets |
March 31, 2023 |
|
December 31, 2022 |
Current assets: |
|
|
|
Cash |
$ |
11,789 |
|
|
$ |
16,989 |
|
Accounts receivable, net |
|
7,334 |
|
|
|
6,830 |
|
Inventory |
|
11,055 |
|
|
|
10,052 |
|
Receivables of FiberCel litigation costs |
|
10,921 |
|
|
|
13,813 |
|
Prepaid expense and other assets |
|
2,367 |
|
|
|
3,015 |
|
Total current assets |
|
43,466 |
|
|
|
50,699 |
|
|
|
|
|
Property and equipment,
net |
|
1,488 |
|
|
|
1,403 |
|
Intangible assets, net |
|
14,220 |
|
|
|
15,069 |
|
Operating lease right-of-use
assets, and other |
|
1,456 |
|
|
|
1,670 |
|
Total assets |
$ |
60,630 |
|
|
$ |
68,841 |
|
|
|
|
|
|
|
|
|
Liabilities and
Stockholders' Deficit |
|
|
|
Current liabilities: |
|
|
|
Accounts payable and accrued expenses |
$ |
15,527 |
|
|
$ |
15,583 |
|
Current portion of long-term debt and revenue interest
obligation |
|
9,678 |
|
|
|
8,990 |
|
Revolving line of credit |
|
- |
|
|
|
- |
|
Contingent liability for FiberCel litigation |
|
15,631 |
|
|
|
17,360 |
|
Current operating lease liabilities and other |
|
588 |
|
|
|
682 |
|
Total current liabilities |
|
41,424 |
|
|
|
42,615 |
|
|
|
|
|
Long-term debt |
|
24,589 |
|
|
|
24,260 |
|
Long-term revenue interest
obligation |
|
5,750 |
|
|
|
5,916 |
|
Long-term operating lease
liabilities |
|
835 |
|
|
|
956 |
|
Other long-term
liabilities |
|
207 |
|
|
|
127 |
|
Total liabilities |
|
72,805 |
|
|
|
73,874 |
|
|
|
|
|
Stockholders' equity
(deficit): |
|
|
|
Common stock |
|
16 |
|
|
|
16 |
|
Additional paid-in
capital |
|
133,771 |
|
|
|
132,939 |
|
Accumulated deficit |
|
(145,962 |
) |
|
|
(137,988 |
) |
Total stockholders' equity (deficit) |
|
(12,175 |
) |
|
|
(5,033 |
) |
Total liabilities and
stockholders' equity |
$ |
60,630 |
|
|
$ |
68,841 |
|
|
AZIYO BIOLOGICS, INC. |
CONSOLIDATED STATEMENT OF OPERATIONS |
(Unaudited, in thousands, except share and per share
data) |
|
|
|
|
|
Three months ended March 31, |
|
|
2023 |
|
|
|
2022 |
|
|
|
|
|
Net sales |
$ |
13,050 |
|
|
$ |
11,495 |
|
Cost of goods sold |
|
6,719 |
|
|
|
7,214 |
|
Gross profit |
|
6,331 |
|
|
|
4,281 |
|
|
|
|
|
Operating expenses: |
|
|
|
Sales and marketing |
|
5,356 |
|
|
|
4,818 |
|
General and administrative |
|
3,679 |
|
|
|
4,025 |
|
Research and development |
|
1,803 |
|
|
|
2,272 |
|
FiberCel litigation costs |
|
1,911 |
|
|
|
88 |
|
Total operating expenses |
|
12,749 |
|
|
|
11,203 |
|
Loss from operations |
|
(6,418 |
) |
|
|
(6,922 |
) |
|
|
|
|
Interest expense |
|
1,544 |
|
|
|
1,215 |
|
Loss before provision of income taxes |
|
(7,962 |
) |
|
|
(8,137 |
) |
|
|
|
|
Provision for income taxes |
|
12 |
|
|
|
12 |
|
Net loss |
|
(7,974 |
) |
|
|
(8,149 |
) |
|
|
|
|
Net loss per share - |
|
|
|
basic and diluted |
$ |
(0.49 |
) |
|
$ |
(0.60 |
) |
|
|
|
|
Weighted average common shares outstanding - |
|
|
|
basic and diluted |
|
16,149,567 |
|
|
|
13,574,058 |
|
Non-GAAP Financial Measures
This press release presents our gross margin,
excluding intangible asset amortization. We calculate gross margin,
excluding intangible asset amortization, as gross profit, excluding
amortization expense relating to intangible assets we acquired in
our acquisition of all of the commercial assets of CorMatrix
Cardiovascular, Inc. in 2017, divided by net sales.
We present gross margin, excluding intangible
asset amortization, because we believe that it provides meaningful
supplemental information regarding our operating performance by
removing the impact of amortization expense, which is not
indicative of our overall operating performance. We believe this
provides our management and investors with useful information to
facilitate period-to-period comparisons of our operating results.
Our management uses this metric in assessing the health of our
business and our operating performance, and we believe investors’
understanding of our operating performance is similarly enhanced by
our presentation of this metric.
Gross margin, excluding intangible asset
amortization, is a supplemental measure of our performance, is not
defined by or presented in accordance GAAP, has limitations as an
analytical tool and should not be considered in isolation or as an
alternative to our GAAP gross margin, gross profit or any other
financial performance measure presented in accordance with GAAP. In
addition, other companies, including companies in our industry, may
use other measures to evaluate their performance, which could
reduce the usefulness of this non-GAAP financial measure as a tool
for comparison.
The following table presents a reconciliation of
our gross margin, excluding intangible asset amortization, to the
most directly comparable GAAP financial measure, which is our GAAP
gross margin (in thousands).
|
Three months ended March 31, |
|
|
2023 |
|
|
|
2022 |
|
|
|
|
|
Net sales |
$ |
13,050 |
|
|
$ |
11,495 |
|
Gross profit |
|
6,331 |
|
|
|
4,281 |
|
Intangible asset amortization
expense |
|
849 |
|
|
|
849 |
|
Gross profit, excluding
intangible asset amortization |
$ |
7,180 |
|
|
$ |
5,130 |
|
Gross margin |
|
48.5 |
% |
|
|
37.2 |
% |
Gross margin percentage,
excluding intangible asset |
|
|
|
amortization |
|
55.0 |
% |
|
|
44.6 |
% |
Aziyo Biologics (NASDAQ:AZYO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aziyo Biologics (NASDAQ:AZYO)
Historical Stock Chart
From Apr 2023 to Apr 2024